comparemela.com

Latest Breaking News On - Argetedproteindegradation - Page 1 : comparemela.com

Arvinas to Present at the Bank of America Securities 2023

NEW HAVEN, Conn., May 03, 2023 (GLOBE NEWSWIRE) Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs.

United statesSean cassidyLas vegasKirsten owensJeff boyleArvinas incBusiness developmentChief financial officerRandy teelSenior vice presidentAmerica securitiesDiscovery engineNasdaq arvnRvinas incProstate cancerProtein degradation

Arvinas Announces Changes to its Board of Directors

NEW HAVEN, Conn., Dec. 16, 2022 (GLOBE NEWSWIRE) Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs.

United statesJohn houstonJeff boyleAsia pacificBrad margusKirsten owensEverett cunninghamExchange commissionArvinas incQuest diagnosticsNorthwestern universityAudit committeeChief executive officerArvina boardChief commercial officerExact sciences

Arvinas Reports Third Quarter 2022 Financial Results and

– On track to initiate enrollment of two Phase 3 trials with ARV-471 in patients with first- and second-line metastatic breast cancer – – Enrolling.

San antonioUnited statesJohn houstonJeff boyleJohn youngKirsten owensCompany board of directorsRegulatory affairsArvinas incExchange commissionDevelopment expensesPfizer incRockefeller universityPhoremost ltdSociety for neuroscienceSan antonio breast cancer symposium

Arvinas to Present at Bank of America Securities Precision

NEW HAVEN, Conn., Sept. 26, 2022 (GLOBE NEWSWIRE) Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs.

United statesJeff boyleKirsten owensArvinas incAmerica securities precision oncology conferenceDiscovery engineNasdaq arvnRvinas incBreast cancerProstate cancerProtein degradationImmuno oncology

Arvinas Appoints Lisa Sinclair as Senior Vice President,

NEW HAVEN, Conn., Aug. 15, 2022 (GLOBE NEWSWIRE) Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs.

John houstonJeff boyleElisa sinclairKirsten owensExchange commissionHead of programArvinas incAlliance management for springworks therapeuticsSenior vice presidentArvinas presidentChief executiveCommercial strategyAlliance managementSpringworks therapeuticsVice presidentProject management

vimarsana © 2020. All Rights Reserved.